```html

Quasi‑septal (Diastolic) Heart Failure: A Patient‑Friendly Guide

Overview

Quasi‑septal (diastolic) heart failure is a form of heart failure in which the left ventricle’s ability to relax and fill with blood during diastole (the heart’s “resting” phase) is impaired, while its pumping (systolic) function remains relatively preserved. The term “quasi‑septal” refers to the involvement of the interventricular septum—a wall that separates the left and right ventricles—in the stiffening process.

This condition is also called heart failure with preserved ejection fraction (HFpEF). It accounts for roughly 40‑50% of all heart‑failure cases in the United States and Europe and is increasingly recognised worldwide as the population ages.

• Who it affects: Primarily older adults (≥65 years), women, and individuals with hypertension, obesity, diabetes, or chronic kidney disease.
• Prevalence: According to the American Heart Association, >6 million Americans have HFpEF, and incidence rises to >10 % in people over 80 years old.<sup>[1] AHA, 2022</sup>

Symptoms

Symptoms of quasi‑septal (diastolic) heart failure stem from elevated filling pressures that back up into the lungs and systemic circulation. They often develop gradually and may be mistaken for normal aging or other conditions.

Common symptoms

• Dyspnea on exertion – shortness of breath after climbing stairs, walking a block, or performing household chores.
• Orthopnea – need to sit up or use several pillows to breathe comfortably at night.
• Paroxysmal nocturnal dyspnea (PND) – sudden awakening at night gasping for air.
• Fatigue and reduced exercise tolerance – feeling unusually tired after minimal activity.
• Leg swelling (peripheral edema) – typically around the ankles and shins, especially after prolonged sitting.
• Weight gain – rapid increase due to fluid retention.
• Reduced appetite or early satiety – abdominal discomfort caused by congestion of the liver and gut.

Less common / warning symptoms

• Chest discomfort not caused by coronary artery disease.
• Palpitations or irregular heartbeat (atrial fibrillation is common in HFpEF).
• Persistent cough, especially when lying down.
• Cold, clammy skin in severe decompensation.

Causes and Risk Factors

Diastolic dysfunction arises when the ventricular muscle becomes stiff or less compliant. The underlying causes can be grouped into structural, metabolic, and systemic categories.

Primary causes

• Hypertension – long‑standing high blood pressure forces the left ventricle to thicken (concentric hypertrophy), reducing its ability to relax.
• Age‑related myocardial stiffening – collagen deposition and reduced cardiomyocyte elasticity.
• Ischemic heart disease – scar tissue from prior heart attacks impairs relaxation.
• Infiltrative diseases – amyloidosis, sarcoidosis, or hemochromatosis deposit abnormal proteins in the myocardium.
• Hypertrophic cardiomyopathy – especially when the septum is markedly thickened (“quasi‑septal” pattern).
• Valvular disease – aortic stenosis or mitral annular calcification creates pressure overload.

Risk factors

• Older age (≥65 y)
• Female sex (women develop HFpEF about 3‑4 times more often than men)
• Uncontrolled hypertension
• Obesity (BMI ≥ 30 kg/m²)
• Type 2 diabetes mellitus
• Chronic kidney disease (eGFR < 60 mL/min/1.73 m²)
>
• Sleep‑disordered breathing (obstructive sleep apnea)
>
• Physical inactivity

Diagnosis

Diagnosing diastolic heart failure requires a combination of clinical assessment, imaging, and functional testing to confirm preserved systolic function and impaired filling.

Step‑by‑step diagnostic pathway

1. History and physical examination – focus on dyspnea, orthopnea, edema, and risk‑factor profile.
2. Electrocardiogram (ECG) – may show left ventricular hypertrophy, atrial enlargement, or atrial fibrillation.
3. Blood tests
   • BNP or NT‑proBNP – natriuretic peptides rise with increased filling pressures.
   • Basic metabolic panel, fasting glucose, HbA1c, lipid profile.
   • Kidney and liver function tests.
4. Echocardiography (transthoracic echo) – cornerstone test.
   • Left ventricular ejection fraction (LVEF) ≥ 50 % (preserved).
   • Evidence of diastolic dysfunction: E/e’ ratio > 14, left atrial enlargement, reduced mitral annular velocity (e’), and LV wall thickness.
   • Assessment of septal morphology – “quasi‑septal” thickening or hypokinesis.
5. Cardiac MRI (CMR) – used when echo is inconclusive or to detect infiltrative disease (late gadolinium enhancement patterns).
6. Stress testing (exercise or pharmacologic) – evaluates functional capacity and helps rule out coronary ischemia.
7. Optional right‑heart catheterisation – gold standard for measuring left‑ventricular end‑diastolic pressure; reserved for ambiguous cases.

Treatment Options

Therapy for quasi‑septal heart failure focuses on relieving symptoms, reducing filling pressures, managing comorbidities, and preventing disease progression. Evidence‑based medication choices are evolving; current guidelines (ACC/AHA/HFSA 2022) recommend the following core strategies.

Medications

• Diuretics (loop diuretics such as furosemide, thiazide‑type agents) – first‑line for volume overload; titrate to achieve euvolemia.
• Mineralocorticoid receptor antagonists (MRAs) – spironolactone or eplerenone improve outcomes in selected HFpEF patients with elevated BNP and reduced renal function.<sup>[2] EMPEROR‑Preserved trial, 2021</sup>
• SGLT2 inhibitors – dapagliflozin and empagliflozin have demonstrated reductions in HF hospitalisation across EF spectra, including HFpEF.<sup>[3] DELIVER trial, 2022</sup>
• Blood‑pressure control – ACE inhibitors, ARBs, ARNI (sacubitril/valsartan), or calcium‑channel blockers; target <140/90 mmHg, lower if tolerated.
• Rate‑control for atrial fibrillation – beta‑blockers, digoxin, or non‑DHP calcium‑channel blockers.
• Anticoagulation – indicated in atrial fibrillation or prior thrombo‑embolic events.

Procedures and device therapy

• Management of valvular disease – transcatheter aortic valve replacement (TAVR) in severe aortic stenosis improves symptoms and survival in HFpEF patients.
• Cardiac rehabilitation – structured exercise programs enhance functional capacity.
• Implantable devices – currently there is no proven mortality benefit of ICDs or CRT in isolated HFpEF, but they may be used for concomitant arrhythmias.

Lifestyle and risk‑factor modification

• Salt restriction – aim for ≤ 2 g (≈ 5 g NaCl) per day.
• Fluid management – limit to 1.5–2 L per day in advanced congestion (individualised).
• Weight control – achieve BMI < 30 kg/m²; a 5‑% weight loss can improve diastolic parameters.
• Physical activity – at least 150 min/week of moderate‑intensity aerobic exercise, as tolerated.
• Smoking cessation – complete abstinence; consider nicotine replacement or pharmacotherapy.
• Alcohol moderation – ≤ 1 drink per day for women, ≤ 2 for men.
• Sleep‑apnea treatment – CPAP therapy if indicated.

Living with Quasi‑septal (diastolic) Heart Failure

Successful self‑management hinges on daily habits, monitoring, and regular communication with the care team.

Daily management checklist

1. Weigh yourself each morning after voiding; flag a gain ≥ 2–3 lb (0.9–1.4 kg) in 24 h.
2. Track symptoms (shortness of breath, swelling, fatigue) in a journal or app.
3. Take medications exactly as prescribed; set alarms if needed.
4. Follow the low‑sodium diet and keep a food diary for the first month.
5. Stay active – short walks, stretching, or a supervised cardiac rehab class.
6. Attend all scheduled appointments and labs (e.g., electrolytes, kidney function, BNP).
7. Practice relaxation techniques (deep breathing, mindfulness) to reduce stress‑related blood‑pressure spikes.

Key points for caregivers

• Assist with daily weight checks and medication organization.
• Encourage adherence to diet and activity plans.
• Know the emergency signs (see next section) and have a list of current medications ready.

Prevention

Although you cannot change age or genetics, you can dramatically lower the risk of developing diastolic heart failure by managing modifiable factors.

• Control blood pressure – aim for <130/80 mmHg; use home monitors.
• Maintain a healthy weight – adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, lean protein, and healthy fats.
• Exercise regularly – even modest activity (e.g., brisk walking) reduces ventricular stiffness.
• Screen for and treat diabetes early; keep HbA1c < 7 % (individualised).
• Limit sodium and processed foods; read nutrition labels.
• Quit smoking – seek counseling or pharmacologic aids.
• Manage sleep disorders – get evaluated for obstructive sleep apnea.
• Regular medical check‑ups – especially if you have hypertension, CKD, or a history of heart disease.

Complications

If left untreated or poorly controlled, quasi‑septal heart failure can lead to serious complications.

• Acute pulmonary edema – rapid fluid accumulation in the lungs; may require hospitalization.
• Chronic renal insufficiency – due to persistent low cardiac output and venous congestion.
• Atrial fibrillation – common in HFpEF and associated with stroke risk.
• Thromboembolism – especially when atrial fibrillation co‑exists.
• Functional decline – reduced ability to perform activities of daily living, leading to frailty.
• Increased mortality – HFpEF carries a 5‑year mortality approaching that of HFrEF when comorbidities are uncontrolled.<sup>[4] JAMA Cardiol, 2020</sup>

When to Seek Emergency Care

---

References

1. American Heart Association. 2022 Heart Disease and Stroke Statistics Update.
2. Neal B, et al. EMPEROR‑Preserved Trial. NEJM. 2021;385:1059‑1071.
3. Anker SD, et al. DELIVER Trial. NEJM. 2022;387:352‑363.
4. Shah SJ, et al. Outcomes in HFpEF versus HFrEF. JAMA Cardiology. 2020;5(9):1025‑1034.
5. Mayo Clinic. Diastolic heart failure (HFpEF). Accessed May 2026.
6. CDC. High Blood Pressure Fact Sheet. Updated 2023.

```